Tom Roberts, CEO of San Antonio, Texas-based startup Invictus Medical discusses the company's approach to preventing the cranial deformation plagiocephaly, also known as flattening of the skull, that affects up to 30% of newborns.
Cardiologist Dr. Darrel Francis finds himself attempting once again to drag the conversation back from the edge of hyperbole as the market reacts to the lackluster outcome of Medtronic's highly anticipated Symplicity HTN-3 trial of renal denervation in treatment of hypertension.
Neurosurgeon Dr. Philip Starr tells MassDevice.com about Medtronic's new Activa PC+S brain monitoring, recording and stimulating implant and its potential for treating neurological and psychiatric disease.
Biomet's private equity owners announce plans to take the orthopedics giant back on the public market.
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
A group of private PE players including the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and TPG acquired Biomet for $11.4 billion in 2007, placing medtech veteran Jeffrey Binder at the helm.
Vector is Children's Hospital Boston's blog about research and innovation in pediatric and adult medicine. We report and comment on medical innovations and advances – from bench to bedside – touching on scientific, business and policy issues. Our ranks include science writers, physicians, lab researchers, market analysts and others inside and outside the hospital.
A growing number of health care professionals are looking at their patients not just as individuals with unique concerns but also as members of larger groups with common problems and needs. This broader, population-based framework could lead to better health outcomes for more people, according to Jonathan Finkelstein, MD, MPH of Boston Children's Hospital.
Internet entrepreneur and TedMed chairman Jay Walker says the next tech billionaires will be created in the areas of health and wellness.
Jay Walker made his fortune in the world of high tech with internet plays such as Priceline.com, which he founded in 1998 and took public a year later, but the man once dubbed "An Edison of the New Age" by Forbes magazine sees the next big things coming from healthcare.
"What happened in the data processing world is coming to medicine," he told an audience of health care executives in New York this week. "There's no question that the Facebooks of tomorrow are going to be in healthcare."
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Valor Medical and 4 of its top brass admit to concealing required data from FDA regulators while undergoing review for an aneurysm treatment implant.
California biotech company Valor Medical, 4 executives and a consultant admitted to the Dept. of Justice that they concealed information about their Neucrylate diagnostic assay, hiding toxicity reports that were required as the product was undergoing FDA premarket review.